Compare Amylx Pharmaceuticals Inc (AMLX) vs Freshworks Inc (FRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Freshworks Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Freshworks Inc trades at $10.45 (market cap $2.86B). The key difference: Freshworks Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FRSH | |
|---|---|---|
Market Cap | $1.98B | $2.86B |
Sector | Health | Technology |
52-Week High | $18.70 | $14.77 |
52-Week Low | $7.64 | $6.88 |
Enterprise Value | $1.70B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
FRSH trades at $10.36, down 0.38% on the day, with a bullish technical signal from moving averages and an overall analyst consensus split evenly between Buy and Hold. The company reported strong revenue growth to $838.81M in 2025, turning profitable with a net income of $183.72M, and recently announced Q2 2026 earnings will be released on August 4, 2026. Recent news highlights include a partnership with Vanquis and AI product enhancements.
Outlook remains positive with Wall Street projecting a 26% upside, supported by robust cash flow and margin expansion. Key risks include competitive pressures in SaaS and execution on AI initiatives. The stock presents a value opportunity given its P/E of 16.86 versus sector averages, but investors should monitor Q2 earnings for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
